Digital Health Global
JANUARY 25, 2024
Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.
Digital Health Global
JANUARY 8, 2024
A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively. Medable, which ranked in the top 8% of software companies on the 2023 Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Society for Participatory Medicine
AUGUST 17, 2022
For a person like me, who is impacted by a rare, neurological, and incurable disease, it’s my mission to ensure that patients’ perspectives are represented early and throughout drug development. We plan to gather these stakeholders at the upcoming Huntington Study Group conference this November 3-5 in Tampa, FL, to develop next steps.
Digital Health Global
APRIL 10, 2023
Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics. Aviceda Glycotech looks forward to this collaboration aimed at developing the next generation of cancer checkpoint immune therapeutics in Belfast. “It CAMBRIDGE, Mass.–(BUSINESS
Society for Participatory Medicine
JANUARY 27, 2022
But returning to Erin Moore’s point, how do we get researchers, clinicians, and industry engaged to listen to patients in clinical trial design, pharma/biotech drug development and health tech capability? It builds trust to uncover unmet needs, provide solutions, and yield powerful, measurable results.
Digital Health Global
MARCH 29, 2023
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
mHealth Insight
APRIL 24, 2018
On Thursday the 26th April 2018 we’ll be presenting on Mobile First Clinical Trial Design at the Global Clinical Trials Connect 2018 Conference in London. With the right commitment and attention to detail, contract research organizations (CROs) and pharmaceutical companies can drive collaboration with greater efficiency.
Expert insights. Personalized for you.
88 
Let's personalize your content